Vanguard Capital Management
TVTX icon

Vanguard Capital Management’s Travere Therapeutics TVTX Stock Holding History

Vanguard Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233M Buy
4,108,694
+62,882
+2% +$2.79M 0.01% 1040
2026
Q1 		$120M Buy
+4,045,812
New +$121M ﹤0.01% 1367

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Capital Management's TVTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Travere Therapeutics (TVTX) stake by 1.6% in Q2 2026, buying an estimated $2.79M and bringing the position to 4,108,694 shares worth $233M. The position accounts for 0.01% of the portfolio, ranked #1040.

Vanguard Capital Management first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Vanguard Capital Management held 4,108,694 shares of Travere Therapeutics worth $233M as of Q2 2026.
  • Vanguard Capital Management bought 62,882 Travere Therapeutics shares in Q2 2026, an estimated $2.79M.
  • Travere Therapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1040 holding.
  • Vanguard Capital Management first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.